Cogent Biosciences Inc
Deschisă
33.44 -0.39
Rezumat
Modificarea prețului
24h
Minim
33.24
Maxim
34.83
Venit | 947K -96M |
|---|---|
EPS | -0.52 |
Angajați | 258 |
EBITDA | 537K -94M |
Următoarele câștiguri | 2 nov. 2026 |
|---|
Capitalizare de piață | -608M 6B |
|---|---|
Deschiderea anterioară | 33.83 |
Închiderea anterioară | 33.44 |
Cogent Biosciences Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Cogent Biosciences Inc Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.